Skip to Content
Stock Analyst Update

Pandemic Headwinds Pressure AbbVie’s Second Quarter

We don’t expect any major changes to our AbbVie fair value estimate for the narrow-moat company.


We don’t expect any major changes to our AbbVie (ABBV) fair value estimate after the firm reported second-quarter results that were slightly below our expectations but ahead of S&P CapIQ consensus projections. The results included Allergan for the first time, and the integration appears to be tracking smoothly despite the heavy COVID-19 pressures on several of Allergan’s more elective treatments. We expect the Allergan business will help AbbVie diversify away from heavy U.S. biosimilar Humira competition in 2023, but the upcoming loss of sales from a very high-margin drug is still a key concern, leading to our narrow moat rating for AbbVie rather than the wide moat rating carried by most Big Pharma companies.

In the quarter, the Allergan acquisition helped boost total sales by 26%, but sales would have fallen by 5% excluding Allergan due to COVID-19 pressures. We expect pandemic pressures to ease through the rest of the year as the healthcare systems adapts. However, given the more elective nature of several of the Allergan-acquired products, such as cosmetic treatment Botox, we expect sales traction will return more gradually for AbbVie versus the drug industry. Nevertheless, AbbVie’s legacy platform, including immunology drugs Humira, Skyrizi, and Rinvoq along with cancer drug Imbruvica, are posting steady gains. The underlying critical nature of the diseases these drugs target, along with drug administration outside of the doctors’ office, likely support the resilience of these drugs despite the COVID-19 pandemic.

On the pipeline front, AbbVie continues to make strides. Recent atopic dermatitis data for Rinvoq suggests a highly competitive drug in a major new indication. Additionally, recent Skyrizi data showed better head-to-head efficacy in psoriasis versus Novartis’ Cosentyx, which should help AbbVie gain more share in new patient starts. Also, the approval for Oriahnn in uterine fibroids opens up a significant new indication for the drug.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Damien Conover does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.